Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
SPAC & De-SPAC Trading Stats (09/29/26) SPAC momentum picked up as $XRPN surged 22% on strong volume and $RFAI added another 6%, while De-SPAC volatility stayed elevated with $PFSA leading gains and $NIVF collapsing 79%. SPACs (DA partner): – $XRPN (Evernorth Holdings) +21.99%…
WATCHLIST Sept 24 2026 Benzinga PreMarket Gainers (% change and volume) $SRZN $GCTK $BEZ $GLND $PFSA $SOXS $WETO $NCPL $LU Read our Benzinga Review here: https://t.co/DbZGLBN9ND https://t.co/fxovw5MvKj
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| HRT FINANCIAL LP 10 percent owner | Aug 13, 2026 | Sale | 42,411 | $37.66K |
| HRT FINANCIAL LP 10 percent owner | Aug 12, 2026 | Purchase | 5,585 | $5.38K |
| HRT FINANCIAL LP 10 percent owner | Aug 11, 2026 | Sale | 2,280 | $2.21K |
| HRT FINANCIAL LP 10 percent owner | Aug 10, 2026 | Purchase | 4,016 | $3.79K |
| HRT FINANCIAL LP 10 percent owner | Aug 4, 2026 | Purchase | 1,368 | $1.31K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-35.82M |
| 2024 | $0 | — | $-9.23M |
| 2023 | $0 | — | $-10.28M |
Stock data for PFSA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics